Innovations in Pharmaceuticals and Their Clinical Applications
Tracking # 20-956884
Price not reported
There are no ratings for this course
Learn moreCourse overview
This program looks at the latest pharmaceutical advances in eyecare with a focus on the most recent FDA approved agents. It is a fast paced review of therapeutics that currently or soon will affect eye care including indications, dosing and unique aspects of the therapies. The pipeline for the next 3 years will be explored with an emphasis on the most innovative prescription medications for ocular disease management.
Subject areas
This course counts toward the state boards and subject areas below.
Texas Optometry Board
Optometrist
Disclosure statements
I have read and will comply with the COPE requirements for course qualification. I further
agree to notify COPE in writing should any information provided, including financial/proprietary
information, change at any time during the three year qualification period of this course.
I agree that I will keep my presentation free from commercial interest or bias. I will maintain
independent control over the content of my presentation, so that it is balanced, objective,
presented with scientific rigor and not be for the purpose of promoting products, equipment,
etc. (Therefore, my presentation should not be perceived by attendees as a commercial.) I
further agree that I will not change the basic content of my presentation following approval.
I agree to disclose to the audience the existence of any significant financial/professional
relationships with the manufacturer(s) of any commercial product(s) and/or the provider(s) of
any commercial service(s) discussed in the educational presentation. (Said relationships can
include such things as grant/research support, employment, consulting and/or speakers bureau
arrangements, major stock ownership, etc.) I will disclose any of these relationships, whether
or not there is direct commercial support for the CE activity. This disclosure is made to provide
the audience the information on which they can make judgments as to a presenter’s objectivity.
I agree to disclose the attendees; a) when products or procedures being discussed are off label,
unlabeled, experimental, and/or investigational (not FDA approved); b) any limitations on the
information that is presented, such as data that are preliminary or that represent ongoing
research, interim analyses, and/or unsupported opinion.
I agree I have an ethical responsibility to make appropriate decisions related to my
presentation, and all issues involving financial remuneration.